MyChesCo on MSN9h
Breakthrough Gene Therapy OCU410 Could Save Millions from Vision Loss – Phase 2 Milestone Achieved!
Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the Phase 2 portion of its ArMaDa clinical trial for ...
ophthalmologytimes15h
Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...
Hosted on MSN19h
GenSight’s Optic Neuropathy gene therapy sustains efficacy over five years
The five-year trial saw patients who received a single injection of Lumevoq sustaining clinical recovery in a rare condition ...
ophthalmologyadvisor5d
Susvimo Approval Expanded to Include Diabetic Macular Edema
The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.
optometryadvisor6d
Optometrists Play a Critical Role in Macular Hole Management
Optometrists may not surgically repair macular holes, but they play a crucial role in managing visual outcomes in these ...